Cargando…
Cannabinoid treatment for autism: a proof-of-concept randomized trial
BACKGROUND: Endocannabinoid dysfunction in animal models of autism spectrum disorder (ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this placebo-controlled double-blind comparison of two oral cannabinoid solutions in 150 participants (age 5–21 years) with ASD. ME...
Autores principales: | Aran, Adi, Harel, Moria, Cassuto, Hanoch, Polyansky, Lola, Schnapp, Aviad, Wattad, Nadia, Shmueli, Dorit, Golan, Daphna, Castellanos, F. Xavier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860205/ https://www.ncbi.nlm.nih.gov/pubmed/33536055 http://dx.doi.org/10.1186/s13229-021-00420-2 |
Ejemplares similares
-
A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ
por: Schnapp, Aviad, et al.
Publicado: (2022) -
Lower circulating endocannabinoid levels in children with autism spectrum disorder
por: Aran, Adi, et al.
Publicado: (2019) -
Mediators of Placebo Response to Cannabinoid Treatment in Children with Autism Spectrum Disorder
por: Aran, Adi, et al.
Publicado: (2023) -
Blood RNA Sequencing Indicates Upregulated BATF2 and LY6E and Downregulated ISG15 and MT2A Expression in Children with Autism Spectrum Disorder
por: Voinsky, Irena, et al.
Publicado: (2022) -
The cannabinoid receptor 1 is involved in renal fibrosis during chronic allograft dysfunction: Proof of concept
por: Dao, Myriam, et al.
Publicado: (2019)